Page 15 - Compass Pathways News Today

TUESDAY, Aug. 1, 2023 (HealthDay News) -- One dose of the hallucinogenic ingredient in "magic mushrooms" may help some people with anorexia move past their preoccupation with body image, an

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 3,460,000 shares, an increase of 44.2% from the June 30th total of 2,400,000 shares. Based on an average daily trading volume, of 286,200 […]

For biotechs developing psychedelic therapies, good news comes in many forms.

10-woman study found the psychoactive compound to be safe, positively perceived

If successful, they could herald a new era for treating anorexia, which has the highest mortality rate of any psychiatric condition (more than 5 per cent, reported JAMA Psychiatry in 2011).

North Star Investment Management Corp. grew its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPS – Free Report) by 1,220.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,300 shares of the company’s stock after purchasing an additional 3,050 shares […]

13.07.2023 - Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.Authors highlight the need for clarity in terminology and ... Seite 1

When Jason Wallach started researching psychedelic compounds just over a decade ago, he expected he would spend his career laboring in obscurity.

When Jason Wallach started researching psychedelic compounds just over a decade ago, he expected he would spend his career laboring in obscurity.

Over the past few years, the conversation surrounding recreational and medical use of psilocybin has shifted due to growing evidence of its significant mental health benefits. This...